MTRC

In France, reimbursements for hospital procedures are made solely via a DRG system, which is called “Groupe Homogène de Maladies” (GHM). All hospitalizations, as well as day case procedures and ambulatory treatments, are reimbursed via DRG. However, there is a possibility of add-on reimbursement (on top of the DRG tariff) via LPPR List. Add-on reimbursement is possible for selected implantable (Title III) or invasive non-implantable (Title V) devices. MTRC released a White Paper with a summary of clinical evidence requirements for the LPPR List process for implants and invasive devices in France. In this White Paper, we identified evidence requirement pitfalls that act as a barrier to listing in the LPPR based on analyzing five recent HAS reports with negative recommendations from different medical disciplines. The analysis was performed in January 2024. Read more and request a White Paper here: https://lnkd.in/edGRdwsd

In mid-August 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another four completed projects. The projects were dedicated to the topics of support for families with a parent suffering from cancer, modeling routine risk screening in children, reducing problematic media use, promoting treatment motivation in people with computer game addiction and Internet addiction, and follow-up care for gestational diabetes: https://lnkd.in/e4CrGdeW

In France, reimbursements for hospital procedures are made solely via a DRG system, which is called “Groupe Homogène de Maladies” (GHM). All hospitalizations, as well as day case procedures and ambulatory treatments, are reimbursed via DRG. However, there is a possibility of add-on reimbursement (on top of the DRG tariff) via LPPR List. Add-on reimbursement is possible for selected implantable (Title III) or invasive non-implantable (Title V) devices. In this White Paper, we identified evidence requirements for national add-on reimbursement via the LPPR List process based on an analysis of five recent HAS reports with positive recommendations. Cases included technologies with different levels of added clinical value (II, III, IV, and V). A review of five cases is followed by recommendations in relation to evidence generation for medical technologies in France, and factors influencing the decision-making of HAS. The analysis was performed in February 2024. Read more and request a White Paper here: https://lnkd.in/enzHs9SE

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2024. Five recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neuromodulation, orthopedic, and spine devices: https://lnkd.in/d5Wurrjy

Clinical and economic evidence is essential for obtaining market access for innovative medical technologies in Europe. Evidence is required to assist reimbursement (e.g. creation of procedure code in Austria, Belgium, France, and the Netherlands) and funding (e.g. obtaining coverage in England and Switzerland) for hospital and ambulatory technologies. In some countries, only clinical evidence is required, while in others, economic data is required as well (Belgium, England, the Netherlands, and Switzerland). Companies struggle to understand what kind of data is required to support reimbursement processes. How many studies are necessary? What should be the duration of follow-up? What outcomes should be considered? What comparator should be selected? MTRC helps medical technology companies reduce uncertainty about evidence requirements of key European reimbursement, funding, and HTA authorities and develop a clear plan to address key gaps with clinical and economic evidence. Learn more and contact us to discuss your needs here: https://lnkd.in/ehYAkxFh

NICE recently introduced a new centralized approach to prioritizing topics for its guidance and a decision-making body - a prioritization board. In July 2024, the decisions of the prioritization board were first published by NICE. Sixteen topics were prioritized, twenty were not prioritized, and one was withdrawn: https://lnkd.in/esPEpHpp

MTRC offers a cost-effective and fast approach to developing early value dossiers for medical technologies. MTRC is the leading provider of market access services for the med tech industry in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We provide regular consulting services to 56% of the top 30 med tech companies and multiple SMEs. The challenge that every innovative medical technology company faces, is communicating the value of medical technology to different stakeholders: 1️⃣ Why is this specific healthcare problem important (mortality, morbidity, impact on quality of life, cost-of-illness)? 2️⃣ What are the current treatment options and what are their limitations? 3️⃣ What is the size of the population with high unmet needs? 4️⃣ What is the proposed novel solution? 5️⃣ Is the treatment/diagnostic option safe and effective? 6️⃣ What are the economic consequences to the hospital and health care system? 7️⃣ What are the organizational requirements for the introduction of a novel method? Historically, these questions were answered by separate publications in peer-reviewed journals and marketing materials. However, these publications are typically not comprehensive enough, lack important information, and are too unstructured to support discussion with various stakeholders including clinicians, reimbursement authorities, and payers. MTRC offers the service of the development of full and early value dossier to support market access, marketing, and business development activities for medical device and IVD companies. An early value dossier is a relatively short (twenty to twenty-five pages) document, based on a systematic but limited search with a focus on the key messages and data. The key objective of the early value dossier is to develop a solid overview of the value proposition at the lowest possible cost. Why choose MTRC for support with the development of an early value dossier? The key factor is that we match deep reimbursement and evidence synthesis expertise. We also acknowledge the budget limitations of the med tech industry. We offer a cost-effective approach with the provision of high-quality (we are ISO 9001:2015-certified, and our average NPS is 10/10) but affordable (15% of our business comes from SMEs) service to our clients. Learn more and contact us to discuss your needs here: https://lnkd.in/dyA4ZdS8  

In early July 2024, Dutch Organization for Health Research and Development (ZonMw) awarded seventeen projects under the Efficiency Research program, including four projects on e-health, two projects on diagnostic imaging techniques, two projects in orthopedics, one project on abdominal surgery, one project in gynecology, and one project in the cardiovascular area: https://lnkd.in/erPUyRuY

Strategic recommendations on the topic of market access pathways for medical technologies. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We provide regular consulting services to 56% of the top 30 med tech companies and multiple SMEs. MTRC offers a service of development of comprehensive strategies to establish reimbursement and funding for medical technologies in Europe. Multiple situations may call for reimbursement strategy support, for example: 1️⃣ Technology is new and no coding and reimbursement are available 2️⃣ Coding and reimbursement are available, but the tariff is low and does not cover the cost of a device 3️⃣ Coding and reimbursement are available, and the tariff is sufficient, but there are restrictions on the target population for the procedure The reimbursement strategy includes an understanding of the relevant pathways (including innovative payment schemes), stakeholders involved, the process, data and evidence requirements, timelines, and deadlines for applications. With MTRC you can avoid the hassle of contracting multiple vendors by working with a single professional provider of services in the European region. Finally, we acknowledge the budget limitations of the med tech industry. We offer a cost-effective approach with the provision of high-quality (we are ISO 9001:2015-certified, and our average NPS is 10/10) but affordable (15% of our business comes from SMEs) service to our clients. Learn more and contact us to discuss your needs here: https://lnkd.in/eGexB9uJ

On August 8, 2024, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 197 and 093 with changes to be implemented no later than October 4, 2024. Thirteen new procedure codes related to cardiovascular, endoscopy, gastrointestinal, interventional radiology, neurology, gynecology, orthopedics, spine, and robotic surgery areas, and four new diagnostic codes were introduced: https://lnkd.in/eHx9VAvT